Malignant Ascites Treatment Market Revenue Opportunies By Key Vendors PharmaCyte Biotech Inc., Sequana Medical, Fresenius SE & Co. KGaA, BioVie, BD, Medtronic plc, and GI Supply

Ascites is the condition characterized by formation of excessive fluid in the abdominal cavity, particularly in the peritoneal cavity. It causes when the body is unable to eliminate out fluids. When ascites is developed due to cancer, it is called as malignant peritoneal effusion or malignant ascites. Malignancies that are most commonly associated with malignant ascites are cancers of breast, liver, ovary, lungs, lymphoma, and colon. In ascites condition, lymph glands in the body gets blocked and lead to ascites symptoms including low blood pressure, loss of sleep, fatigue, and skin problems.

Key symptoms in malignant ascites are abdominal pain or discomfort, shortness of breath, swelling of the abdomen, leg or ankle swelling, constipation, and weight gain. Diagnosis of ascites can be done by ultrasound, x-ray test, CT scans, and physical examination. The survival rate of these patients is very low, although with suitable treatment such as paracentesis, chemotherapy, and surgeries are available. Various conventional treatment for malignant ascites include chemotherapy, shunting, paracentesis, and use of drugs such as spironolactone and spironolactone. Cirrhosis of the liver is the most common cause of ascites but other conditions such as kidney failure, heart failure, cancer or infection can also cause ascites.

Download PDF Brochure of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/1775

Malignant Ascites Treatment Market – Dynamics
Rising prevalence of cirrhosis is a major factor for growth of the malignant ascites market. For instance, according to a study published in World Journal of Gastroenterology 2011, over 50% of patients develop ascites within 10 years diagnosis. According to a published article in Journal of Clinical and Translational Hepatology 2014 showed advancements in ascites condition is related with poor prognosis, with a mortality of 15% at one year and 44% at the five year follow up. Moreover, favorable reimbursement policies like 2010 Patient Protection and Affordable Care Act (PPACA) and increasing incidence of cancer are also propelling the market growth. For instance, according to 2018 American Cancer Society report, cancer was responsible for 609,640 deaths in the U.S. Furthermore, key company adopt market strategies such as acquisition are propelling the market growth, For instance, 2016 NanoAntibiotics acquired LAT Pharma LLC, an early-stage biotechnology company famous for developing new medicines to treat life-threatening complications of liver cirrhosis.

However, stringent regulations and complications associated with ascites treatment such as internal bleeding after paracentesis treatment, exposure of radiation in chemotherapy may hinder growth of the market over the forecast period. For instance, According to report published in 2017 Experimental & Molecular Medicine showed that radiation can induce toxicities in non-tumorous liver tissues that may limit the course of therapy or have serious chronic side effects, including late fibrosis.

Request for Discount Before Buying Research Report: https://www.coherentmarketinsights.com/insight/request-discount/1775

Malignant Ascites Treatment Market – Competitive Landscape
Key players operating in the global malignant ascites treatment market include PharmaCyte Biotech Inc., Sequana Medical, Fresenius SE & Co. KGaA, BioVie, BD, Medtronic plc, and GI Supply, Actavis Elizabeth LLC, Mylan Pharmaceuticals Inc., GE Healthcare, Trion Pharma, Siemens AG, and Fresenius Biotech. Major players are focused towards adopting strategies such as collaboration, and increasing R&D funding to strengthen their product portfolio and retain their position in the market, For instance, BioVie’s Lead Compound BIV201 received FDA Orphan-Drug Designation for the treatment of ascites in 2016

Malignant Ascites Treatment Market – Taxonomy
On the basis of treatment type, malignant ascites treatment market is segmented into:
• Therapeutic Treatment
• Surgical Treatment
On the basis of application, malignant ascites treatment market is segmented into:
• Ovarian Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Colorectal Cancer
• Carcinoma of Unknown Primary
• Others
On the basis of geography, malignant ascites treatment market is segmented into:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.